RPGLIFENSE28 January 2025

RPG Life Sciences Limited has informed the Exchange about Investor Presentation

RPG Life Sciences Limited

January 28, 2025

To,

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, ‘G’ Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051.

BSE Limited Corporate Relationship Department Floor 25, P.J. Towers Dalal Street Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Investor Presentation - Financial Results

Please find enclosed herewith a copy of Investor Presentation with respect to Unaudited Financial

Results of the Company for the quarter ended December 31, 2024.

Kindly take the above on record.

Thanking you,

Yours faithfully, For RPG Life Sciences Limited

Rajesh Shirambekar Head – Legal & Company Secretary

Encl: as above

Investors’ Presentation 9M FY25

Disclaimer

This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.

The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the “Company”), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment, therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.

RPG Group: Powered by Passion, Driven by Ethics

RPG Enterprises was founded in 1979. The group currently operates various businesses in Infrastructure, Technology, Life Sciences, Plantations and Tyre industries. The group has business history dating back to 1820 AD in banking, textiles, jute and tea. The Group grew in size and strength with several acquisitions in the 1980s and 1990s. RPG Group is one of India’s fastest growing conglomerates with 31,000+ employees, presence in 135+ countries and annual gross revenues of USD 4.8 Bn

EPC major in infrastructure segments like T&D, Civil, Transportation, Oil & Gas, Renewables & Cables

One of India’s leading tyre manufacturers

Global technology consulting and IT services company

Integrated pharma company in formulations and synthetic APIs

Technology solutions company catering to energy and infrastructure

One of India’s largest plantation companies producing tea, rubber, etc.

RPG Life Sciences: An Integrated Pharmaceutical Company APIs to Formulations; R&D to Manufacturing to Marketing

RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.

Leader in Immunosuppressants

Domestic Formulations (DF)

Develop, manufacture and market branded formulations in India & Nepal

APIs 15%

International Formulations (IF) 19%

Domestic Formulations (DF) 66%

International Formulations (IF)

Develop, manufacture and sell oral solid dosage formulations in the generics and branded generics space across regulated and emerging Markets

APIs

Develop, manufacture and sell high value synthetic APIs in the general therapeutic category

9 Therapies represented by High Equity Brands

50+ Markets Presence

3 Manufacturing Facilities

1300+ Employees

RPG Life Sciences: Product Portfolio Strong ‘Textbook’ brands ; ↑ Chronic and Specialty therapies

Key Therapies

Nephrology

Rheumatology

Oncology

Pain Management

Gastroenterology

Neuropsychiatry

Cardio- Diabeto

Urology

Legacy Portfolio

Immunosuppressants

Textbook Brands

DF Key Products

New Portfolio

Specialty

Chronic

Life Cycle Management (Existing Products)

Azathioprine

Spironolactone

Mycophenolate Mofetil

Diphenoxylate HCl

Cyclosporine

Tacrolimus

Naproxen

Haloperidol

Trastuzumab

Adalimumab

Bevacizumab

Rituximab

Tofacitinib

Sacubitril+ Valsartan

Vildagliptin

Teneligliptin

Dapagliflozin

Solifenacin

Disopyramide Phosphate

Ferric Carboxymaltose

Denosumab

API 15%

IF (IF) 19%

DF 66%

IF Key Products Generics - Azathioprine, Sodium Valproate PR, Nicorandil, Sertraline Branded Generics – Siloxogene, Azoran, Mofetyl, Arpimune ME, Dyzantil, Dipsope

API Key Products APIs - Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, Nicorandil, Pantoprazole, Diphenoxylate

Business Operations

Journey of RPG Life Sciences

Process Excellence Product Portfolio, People, Business Processes

Fundamentals Fixation Sales Hygiene, People, Organization

Sustainable Profitable Growth Revenues, Volumes, Margins

Benchmark Performance Profitability, Leverage, Liquidity Ratios

Scale-up

Building a Strong-Consistent-Profitable Business

Driving Transformation Agenda

Focusing on Execution

Upticking Growth Trajectory

Energizing Happy Teams

>10

Targeted Tenets

High Impact Projects

Bold Moves

Diverse Initiatives

Driving Transformation Agenda

Tenet 1

Propel growth of DF Business

Tenet 2

Accelerate Migration to Higher Margins

Tenet 3

Build Strategic Assets/ Footprints

Tenet 4

Accelerate IF Business

Tenet 5

Embrace Digitalisation to transform Business

Tenet 6

Strengthen organization to deliver core strategy

Focusing on Execution

Multiple Projects targeted to Transform Business, ↓ Costs, ↑ Quality, Add New Business

Comprehensive Business Transformation Project

Innovation Projects

Plants Infra Modernization-Capacity Expansion Projects

Digitalization Projects

COGs Reduction Projects

M&A Projects

Product Re-engineering Projects

Med-tech Projects

Quality Enhancement Projects

ESG Projects

Project Charters, Workstreams, Scope, Review, KPIs Measurement

Upticking Growth Trajectory

Bold Move 1

Galvanizing Organization to an “Inspiring Purpose”: Framing and embedding in the organisation

Bold Move 2

“Small Brands” to Building “Mega Brand of 100 cr +; future 500 cr OTC”: Naprosyn

Bold Move 3

“Small Product” to Building “Mega Rx Portfolio of 100 cr +; Potential 200 cr” : Immunosuppressants

Bold Move 4

“Small API” segment to Building “Formidable API Business”: Manthan

Bold Move 5

Predominant “Domestic Play” to “Expanded Global Play” : Capex infusion ~140 cr

Bold Move 6

“Operations” Focus to “Sustainable Operations” Focus: ESG

Energizing Happy Teams: Happiness Framework People Initiatives for a Building Happy Performance focussed Culture

I Feel Valued

You Excel. We Applaud. Motivation continuum

I Live a Purposeful & Balanced Life

RPGLS Values Champions Living organizational values

I Love My Work

RPGLS Heroes Outperformance recognition

High Happiness Quotient

I Feel Connected

RPGLS Happiness Forums Leadership Connect – Month & Quarter

I am Growing

We Skill. You Grow. Competency building continuum

Akanksha Career development

I cherish our Culture

RPGLS Parivar Tyohar-Utsav Shrankhla Digital RPGLS family get- together

Glimpses of Actions Product Lifecycle Management- Naprosyn

LCM Strategy

LCM Application to Legacy Brand - Naprosyn

New Strengths

New Dosage Forms

New Molecule Combinations

New Indications

New Customer Segments

New Patient Segments

New Geographies/Customers

More to Follow

On its way to become the 1st 100 Cr Brand

Glimpses of Actions: Sales and Marketing: Digitalization- RPG Serv

RPG Serv: Anytime Anywhere Doctor Support Initiative

10 versions launched across 10 diverse Customer segments

Therapy customization across services to ensure engagement

>90K doctors enrolled- Excellent Feedback

Glimpses of Actions: Sales and Marketing : AI at RPGLS- LSAI

Glimpses of Actions Manufacturing and Quality: Digitalization across Manufacturing Functions

Digital Retina Scanner

• Biometric Access with IRIS/ Retina Scanner enables consistency of electronic records and signatures

• Access to only

qualified professionals, Batch Management, Recipe Management, Au dit logs

Intelligent Chilling Plant Manager

IOT based AHU monitoring system

Power Management System

• Implementation of Utility Asset Management Systems with access over IoT, supported by Customized Algorithms for Efficient Monitoring, Control & Analytics

• Operates Pumps

•

& Chillers according to Operating Hours to maintain equal run time

• Automatically change over Working pump to Standby if Pump fails during operation

Safe, reliable, efficient, and compliant operation of electrical distribution systems, and connected assets enabling at all times

e-QMS: Digital platform to track all 6 quality parameters

e-DMS: Digital platform to manage manufacturing/quality documents

e-LMS: Digital platform to track training sessions on CGMP

Quality Functions

Glimpses of Actions Sustainability- ESG

Initiatives

• Carbon emission reduction

• Energy Efficiency: Energy Efficient pumps ; Leakages

rectification of compressed air system; High Efficiency chillers/Brine Plant

• Water Management: Recycling of STP water; Rainwater

harvesting

• Waste Management: No landfill waste generation

FY24

↓15% (FY23); ↓27% (FY24)

↑8% (FY23); ↑26% (FY24)

↓7% (FY23); ↓16% (FY24)

↓ 10% (FY23; ↓49% (FY24)

• Product Responsibility- Adherence to stipulated mandates

Strict Quality vigil through Manthan 3 Project

• Diversity- women deployment, occupational health

Targeted initiatives implementation

• Tree Plantation

360

• Employee Well-being: Comorbidity tracking

Done for all factory employees

• Data Integrity: Digital initiatives e.g. e-QMS, e-DMS, e-LMS

Implemented at Ankleshwar; Navi Mumbai

• Cybersecurity: IT assets security through EDR tool

Implemented

(Crowdstrike)

• Best Practices/Systems and Processes across Functions

Sales & Marketing

a t n e m n o r i v n E

i c o S

e c n a n r e v o G

Glimpses of Actions HR: Monthly Townhalls

Hello Happiness Forums: Monthly Townhall for Connect, Recognition and Camaraderie

140+ Awards

100+ Recognitions

1000+ colleagues Celebrated

Glimpses of Actions HR: Employee Development, Motivation and Engagement

Rewards and Recognition: Hi-Flier Function

Employee Engagement

Crowdsourcing Ideas

Employee Motivation

Financial Performance

Q3 FY25 Performance

Revenue from Operations

EBITDA & EBITDA Margin

153.7

172.7

39.8

25.9%

52.5

30.4%

Q3 FY24

Q3 FY25

Q3 FY24

Q3 FY25

(All figures in Rs. Crores except EPS in Rs.)

PBT & PBT Margin

35.5

46.9

23.1%

27.1%

Q3 FY24

Q3 FY25

PAT & PAT Margin

26.5

17.2%

34.9

20.2%

EPS

21.1

16.0

Figures in circle are Margins

Q3 FY24

Q3 FY25

Q3 FY24

Q3 FY25

9M FY25 Performance

Figures in circle are Margins

Revenue from Operations

EBITDA & EBITDA Margin

(All figures in Rs. Crores except EPS in Rs.)

PBT & PBT Margin

455.1

510.3

113.0

24.8%

141.8

27.8%

100.1

98.0

22.0%

19.2%

125.3

24.5%

9M FY24

9M FY25

9M FY24

9M FY25

9M FY24

9M FY25

9MFY25 (Adj)

PAT & PAT Margin

74.4

16.4%

65.9

12.9%

93.1

18.2%

9M FY24

9M FY25

9M FY25 (Adj)

EPS

45.0

39.8

56.3

9M FY24

9M FY25

9M FY25 (Adj)

The reported PBT & PAT margins are post considering exceptional items of Rs. 27.3 Cr towards payment of ULC transfer charges. To be noted is that this impact on P&L statement will get nullified in Q4 FY25 as profit on sale of assets would come in P&L post completion of land assignment deal. The Adjusted figures are without considering the exceptional items

Key Financials Yearly Trends An Un-interrupted Upward Trajectory Continues Unabated

Figures in circle are Margins

(All figures in Rs. Crores except EPS in Rs.)

Revenue from Operations

EBITDA & EBITDA Margin

PBT & PBT Margin

375.6 389.1 440.2

582.1

512.8

510.3

107.5

89.4

70.8

59.9

135.4

141.8

117.8

125.3

91.7

73.2

53.6

13.8%

16.6%

17.9%

20.2%

24.5%

36.5

9.7%

15.9% 18.2%

20.3%

21.0% 23.3%

27.8%

FY20

FY21

FY22

FY23 FY24 9M FY25

FY20

FY21

FY22

FY23

FY24 9M FY25

FY20

FY21

FY22

FY23

FY24

9M FY25 (Adj)

PAT & PAT Margin

87.7

93.1

67.6

51.5

40.0

29.0

7.7%

10.3%

11.7%

13.2%

15.1%

18.2%

FY20

FY21

FY22

FY23

FY24

9M FY25 (Adj)

EPS

40.9

31.1

53.0

56.3

24.2

17.5

FY20

FY21

FY22

FY23

FY24

9M FY25 (Adj)

Margins Yearly Trends- at a glance An Uninterrupted Upward Trajectory continues- EBITDA crosses 27%; PBT* crosses 24% and PAT* crosses 18%

* Adjusted

EBITDA% 27.8%

PBT%* 24.5%

PAT%* 18.2%

23.3%

20.2%

15.1%

20.3%

21.0%

16.6%

17.9%

11.7%

13.2%

18.2%

13.8%

10.3%

15.9%

11.1%

7.7%

11.1% 10.4%

9.3%

4.7%

5.9%

3.9%

4.6%

3.3%

9.8%

8.1%

6.2%

6.0%

0.9%

0.5%

0.2%

0.4% 0.4%

0.4%

8.7%

4.2%

Key Financial Ratios Yearly Trends (ROCE, ROE, D/E) Upward Trajectory continues

ROCE%

ROE%

Debt/Equity Ratio

31.0%

29.7%

28.5%

24.9%

20.9%

23.4%

22.0%

0.22

20.1%

18.5%

16.4%

9.7%

6.7%

0.06

0.01 0.00 0.00 0.00

FY19 FY20 FY21 FY22 FY23 FY24

Company continues to remain Debt-free

9M FY25: Business Segment-wise Performance

Business Segments

Domestic Formulations (DF)

Domestic Formulations contributed 66% to total sales of 9M FY25 • 12% sales growth driven by both Legacy and New products • Growth consistently higher than the market • New products* contribution improving consistently (currently >25%) on account of new

launches in Specialty & Chronic segments and line extensions of legacy products

• Salesforce productivity consistently improving (currently >6 lakhs) • Business driven by 5 Pillar strategy

APIs 15%

IF 19%

DF 66%

International Formulations (IF)

International Formulations contributed 19% to total sales of 9M FY25 • Robust sales growth of 15% • New Products/Customers/Markets contribution continues to improve (currently ~30%) • Business driven by 4 Pillar strategy

API

API contributed 15% to total sales of 9M FY25 • Growth of 8% • Continuous thrust on new customer development • Business driven by 3 Pillar strategy

*Launched FY19 Onwards

294.6

330.6

9M FY24

9M FY25

85.9

98.6

9M FY24

9M FY25

70.9

76.6

9M FY24

9M FY25

RPG Life Sciences ICRA Rating Upgradation in FY24 A- (FY19) to A(FY21) to A+ (FY24)

Long term rating recently upgraded to A+ from A Short term rating reaffirmed at A1

Outlook on long-term rating has been retained as Stable

The rating upgradation factors:

• Strong brands in the Indian Pharmaceutical Industry • Steady growth in Top-line and improving operating margins • A robust capital structure and strong debt servicing indicators based on

o Healthy cash flows o Company continues to remain debt-free o No debt-funded capital expenditure (capex)

• Expansion of product portfolio and geographical presence augur well for growth

prospects

Business Strategy

Domestic Formulations (DF)

• Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • • • Good Customer Coverage - Cardiologists, Diabetologists, Urologists, Nephrologists, Rheumatologists, Oncologists • New Product Launches in New Category – Biosimilars as well as Chronic and Specialty segments

Leading Textbook Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace Leading player in Immunosuppressant category

Business Strategy

5 pillars of profitable Domestic business growth

Product portfolio rejuvenation by building Chronic & Specialty portfolio with new launches

Strategic brand assets building through life cycle management (new line extensions, customer segments, disease segments, etc.)

Customer coverage deepening in targeted therapies by expanding field force and deploying digital

Sales force effectiveness augmentation by competencies building and productivity enhancement initiatives

Profitability improvement by Opex control, efficient manufacturing operations, sales hygiene as well as profitable product mix

International Formulations (IF) Business: Overview and Strategy

• Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa •

Long lasting, impeccable supply track record and business relationship with some of the leading generic players of the world

• High quality and process orientation making us a preferred partner •

Investments in plant upgradation and capacity expansion

Business Strategy

3 pillars of step-wise Global business build up

Build immunosuppressant portfolio

Focus on products with specific/ competitive advantage e.g. -

Products needing Special manufacturing conditions like low RH/Temp Complex generic products Low Competition products

- -

Expand footprints in emerging/select markets like Myanmar, Vietnam, Philippines, Sri Lanka, Egypt, Sudan, Thailand, and South Africa

APIs Business: Business Strategy and Way Forward

• High value, low volume, niche APIs • Mature stable molecules •

Provides backward integration to International Formulations business

•

Footprints across geographies - LATAM, Germany, China, South Korea, Iran, Bangladesh, Egypt, India, etc. Strong customer focus – long-lasting relationship with big pharma and leading generic firms.

Business Strategy

Business continuity

Market/Customer Expansion (Existing Products)

State-of-Art, EU/TGA approved Plant with Enhanced Capacity

Pipeline of Niche Product/Portfolio : - -

Immuno-suppressants Limited Competition products Backward integration of IF/DF

Infrastructure & Backend Capabilities

Manufacturing Facilities

Formulations Unit 1, Ankleshwar

Formulations Unit 2, Ankleshwar

API Unit, Navi Mumbai

F1 unit caters to the domestic and emerging markets

• • Multipurpose plant with dedicated product lines for oral dosage forms including tablets,

liquids and powder

• WHO, Kenya, Nigeria approved • Modernization cum Capacity Expansion underway

F2 unit caters to the regulated markets

• • Dedicated product lines for oral dosage (capsules & tablets) • • WHO, EUGMP (from Hamburg Health authority), Canada, Ethiopia, Kenya, Sudan,

Equipped to handle low RH and low temperature conditions products

Nigeria approved

• Modernization cum Capacity Expansion underway

• MF1: Multipurpose unit catering to emerging markets including India • MF2: Dedicated immunosuppressant facility for regulated and emerging markets including India • MF3: Multipurpose unit catering to regulated and emerging markets including India • WHO, TGA Australia approved & Written Confirmation (WC) received from CDSCO • Approved by WHO GMP from Food and Drug Control Administration (FDCA) – Maharashtra, TGA

(Australia), PMDA (Japan)

• Modernization cum Capacity Expansion underway

Strong Backend Capabilities

Quality

• All critical SOPs harmonized through CQA • Quarterly internal audit of all plants by CQA • All critical deviations, change controls and market

complaints investigation approved by CQA

Regulatory

• Well established & evolved Regulatory function catering to Canada, UK, EU, Australia and emerging markets Expertise of eCTD submissions Integrated project management activities

• •

•

Formulations R&D In addition to Formulations Development of IR, have capabilities to develop modified release & complex generics

• Dossiers gap analysis and fulfilment Tech transfer/site transfer activities • • GLP compliant analytical lab for Development and

Validation of Analytical Methods

Digitalisation Focus Areas

• Quality Management systems : e-QMS, e-DMS, e-LMS. • Access to critical manufacturing equipment through IRIS

scanner

• All QC instruments attached with dedicated software

and server

• All stability chambers with software control •

Secondary packing Complies with EUFMD requirement for Track and Trace.

Awards & Recognitions

RPG Life Sciences recognized as India’s Top 500 Value Creators by Dun & Bradstreet

RPG Life Sciences Awarded with ‘Jamnalal Bajaj Award for Fair Business Practices’

Jamnalal Bajaj Award for Fair Business Practices (2021-22)

RPG Life Sciences Bagged Top Awards of the Industry

Best Patent Award

Best Corporate Citizen Award

New Launch Naprosyn+ bags Brand Award

Journey Ahead

Transformation Agenda will continue to drive All-Round Performance

Revenue Growth

Profit Growth and Focus on Cashflows

Strong Governance

Building Domestic Formulations Business via the identified 5 Pillars

Building Global Business through New Products/Markets/Customers

Formulations and API plants Modernization and Capacity expansion

Continued diligent thrust on cost control measures both in Opex and COGS

All operations within the Framework of strong Corporate Governance

Product Re-engineering

R&D Pipeline in identified niche areas

Process Efficiencies

New Opportunities : M&A

Diligent work on the Comprehensive 7 Pillars identified to Scale-up” business

State-of-art ↑ Capacity PLANTS

Targeted Niche- focus R&D PIPELINE

Institutionalized INNOVATION

TECHNOLOGY enablement

M&As

Lead Therapy ADJACENT Spaces

Talent Development /Acquisition

• Modern,

Cost-efficient; cGMP Compliant; EU/PICS/TGA etc approved

• Higher

Capacity ~2X

• Focused New Product Grid across 3 segments

• R&D

Organisation strengthening

• Institutionalizat

• Technology

• M&A

ion of Innovation – Idea platforms, Rewards, Reviews

Identification and adoption

• All Areas –

Front-end, Back- end Functions

• Innovation

project(s) by each Department

Framework with criteria defined - Target Therapies, Brands Margin

• Identify & explore Adjacencies in RPGLS Strength therapies

• Org structure review & role/skill-gaps identification

• Talent

Development

• Talent

Acquisition in role/Skill-gaps

T H A N K

Y O U

← All Transcripts RPGLIFE Stock Page →

RPG Life Sciences Limited has informed the Exchange about Investor Presentation

Market Movers